PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  08:24 2022-08-12 am EDT
48.47 USD   +0.37%
07:33aPfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Coverage Following Phase 3 Study
MT
06:46aPfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
BU
02:33aGSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Basilea Pharmaceutica announces approval for additional formulation of antifungal Cresemba (isavuconazole) in China

06/24/2022 | 08:12am EDT

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced that its license partner, Pfizer Inc. (NYSE: PFE, 'Pfizer'), has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the intravenous formulation of Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis.

This is the second approved formulation for Cresemba in China, in addition to the oral formulation for invasive aspergillosis and invasive mucormycosis.

David Veitch, Basilea's CEO said: 'We congratulate our partner Pfizer on this additional approval of Cresemba in China. Invasive fungal infections can pose a serious threat to patients. Offering both the oral and the intravenous formulation of Cresemba gives adult patients suffering from invasive aspergillosis and invasive mucormycosis access to the full range of treatment options with Cresemba. China is a very important commercial market, accounting for approximately 20 percent of global sales for newer antifungals.'

Cresemba is approved in 68 countries to date and is currently marketed in 57 countries, including the United States, most EU member states and additional countries inside and outside of Europe. In the twelve months between January and December 2021, total global in-market sales of Cresemba amounted to USD 324 million, a 28 percent growth year-on-year.1

About invasive aspergillosis and invasive mucormycosis

Invasive aspergillosis and invasive mucormycosis are life-threatening mold infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer). Both infections are associated with high morbidity and mortality.

About isavuconazole (Cresemba)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections and cancer. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both anti-infectives and cancer in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as 'believe', 'assume', 'expect', 'forecast', 'project', 'may', 'could', 'might', 'will' or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact:

Peer Nils Schroder, PhD

Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland

Phone: +41 61 606 1102

E-mail: media_relations@basilea.com

E: investor_relations@basilea.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
07:33aPfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
06:46aPfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
02:33aGSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
01:15aHaleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
12:20aHaleon Says it Hasn't Been Notified About Litigation on Zantac Drug
DJ
08/11US Stocks Close Mixed Thursday Following Surprise Producer Price Drop
MT
08/11US Stocks Close Mixed Thursday Following Surprise Producer Price Drop
MT
08/11GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
RE
08/11Sanofi, GSK, Pfizer Shares Fall Amid Growing Concerns Around Zantac Litigation in US
MT
08/11GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,57x
Yield 2022 3,35%
Capitalization 271 B 271 B -
EV / Sales 2022 2,55x
EV / Sales 2023 3,23x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 48,29 $
Average target price 56,53 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-18.22%271 020
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-16.39%272 759
ABBVIE INC.4.93%251 211
NOVO NORDISK A/S6.37%248 905